News Releases Keyword Search Year None202420232022202120202019201820172016 May-15-2019 Oncternal to Present Interim Phase 1/2 Cirmtuzumab Data at ASCO Mar-07-2019 GTx and Oncternal Therapeutics Enter into Definitive Merger Agreement to Create Nasdaq-Listed Clinical-Stage Company Developing a Diverse Pipeline of Novel Cancer Therapies Sep-12-2018 1st Pt Dosed in Phs 1b Clinical Trial of Cirmtuzumab in Combo w/ Paclitaxel in Pts w/ Breast Cancer Jun-01-2018 Oncternal Announces Publication of Data from Phase 1 Trial of Cirmtuzumab in CLL in Cell Stem Cell May-24-2018 Oncternal Announces Clinical Supply Arrangement to Evaluate the Combo of Cirmtuzumab and Ibrutinib Mar-09-2018 UC San Diego Researchers Launch Combination Drug Trial to Eradicate B-Cell Malignancies Feb-15-2018 Oncternal Opens its CIRLL Study, a Combo Trial of Cirmtuzumab with Ibrutinib in B-Cell Malignancies Feb-22-2017 Oncternal Closes $18.4 Million Series B Financing Dec-06-2016 Oncternal’s Pipeline Candidates Featured in Presentations at American Society of Hematology Meeting Aug-30-2016 Oncternal Therapeutics Initiates Patient Dosing in Phase 1 Clinical Trial of TK216 in Ewing Sarcoma Pagination First page « first Previous page ‹ previous … Page 9 Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Current page 16 Page 17 Next page next › Last page last »